Provider Briefing: Citric Acid/Sodium Citrate Availability in 2026

If your patients have been reporting difficulty filling prescriptions for Citric Acid/Sodium Citrate (Bicitra, Cytra-2, Oracit), you're likely already aware that this urinary alkalinizer faces ongoing availability challenges. This briefing provides a concise overview of the current supply situation, prescribing implications, and practical resources to help your patients maintain continuity of care.

Current Supply Timeline

Citric Acid/Sodium Citrate oral solution is not currently listed as an active shortage on the FDA Drug Shortage Database. However, the clinical reality is more nuanced than the official designation suggests.

The medication has experienced intermittent supply disruptions over recent years, driven by several structural factors:

• 2022-2023: Broader pharmaceutical supply chain disruptions affected many liquid oral dosage forms, including citrate-based solutions
• 2024: Supply generally stabilized, though regional pockets of unavailability persisted
• 2025-2026: Availability is adequate at the national level, but individual pharmacies — especially chain retail locations — may not routinely stock the product

The pattern is one of intermittent, localized unavailability rather than a sustained national shortage.

Prescribing Implications

The availability challenges with Citric Acid/Sodium Citrate have several implications for prescribing providers:

Formulation Awareness

Citric Acid/Sodium Citrate is only available as an oral liquid solution in two formulations:

• 500 mg sodium citrate / 334 mg citric acid per 5 mL
• 490 mg sodium citrate / 640 mg citric acid per 5 mL

The liquid-only availability is itself a limiting factor. Liquid medications require specialized manufacturing, have shorter shelf lives, and are stocked less consistently than solid dosage forms.

Consider Therapeutic Alternatives Proactively

Rather than waiting for a fill failure, consider whether a more readily available alternative is clinically appropriate for your patient from the outset:

• Potassium Citrate (Urocit-K): Available as extended-release tablets (5 mEq, 10 mEq, 15 mEq). More widely stocked and manufactured. Preferred for patients on sodium-restricted diets. Requires potassium monitoring, particularly in patients with renal impairment.
• Sodium Bicarbonate: Available OTC as tablets (325 mg, 650 mg). Most accessible and affordable option. Less precise dosing control compared to citrate solutions. Appropriate for patients who can tolerate the sodium load.
• Tricitrates (Cytra-3): Oral solution containing potassium citrate, sodium citrate, and citric acid. May face similar liquid-formulation supply challenges as Cytra-2.
• Potassium Citrate/Citric Acid (Cytra-K): Oral solution using potassium citrate. Better for sodium-restricted patients. Same liquid supply considerations apply.

Compounding as a Backup

For patients who specifically require the liquid citric acid/sodium citrate formulation — for example, patients with dysphagia or those who cannot swallow tablets — compounding pharmacies can prepare the solution from USP-grade ingredients. Note that compounded preparations may not be covered by insurance and typically cost more than commercial products.

Availability Picture: Where Patients Can Find It

Based on current data, availability patterns for Citric Acid/Sodium Citrate break down as follows:

• Chain pharmacies (CVS, Walgreens, Rite Aid): Inconsistent stocking. Many locations do not carry the product routinely and must special-order it.
• Independent pharmacies: Often have better access through multiple wholesalers and are more likely to stock niche liquid products.
• Mail-order/specialty pharmacies: Generally reliable for obtaining the product, though delivery time adds a delay.
• Compounding pharmacies: Reliable as a last resort but at higher cost.

Providers can direct patients to Medfinder for Providers to check real-time pharmacy availability and help patients locate the medication faster.

Cost and Access Considerations

Cost remains manageable for most patients, but it's worth being aware of the landscape:

• Generic retail price: Approximately $25-$35 for a standard supply
• With discount coupons (GoodRx, SingleCare): As low as $5.64-$10
• Brand name (Oracit, Bicitra): $50-$85 without insurance
• Insurance coverage: Typically Tier 1 or Tier 2 on most formularies. Prior authorization is rarely required.

For uninsured or underinsured patients, discount card programs offer significant savings. There is no manufacturer-sponsored savings program specific to this generic medication, but programs like NeedyMeds and RxAssist can help eligible patients identify broader assistance options.

Tools and Resources for Your Practice

Consider integrating these resources into your practice workflow:

• Medfinder for Providers: Real-time pharmacy stock checking tool. Helps clinical staff verify availability before sending prescriptions to pharmacies that may not have the medication.
• FDA Drug Shortage Database: Monitor for any official shortage designations at accessdata.fda.gov
• ASHP Drug Shortage Resource Center: Additional shortage tracking and clinical guidance

Workflow Recommendation

When prescribing Citric Acid/Sodium Citrate:

1. Verify with the patient's preferred pharmacy that the medication is in stock or can be ordered
2. Include a note on the prescription allowing therapeutic substitution where appropriate (e.g., "May substitute Potassium Citrate if Sodium Citrate/Citric Acid unavailable — contact prescriber")
3. Proactively discuss backup options with the patient
4. Consider prescribing 90-day supplies where clinically appropriate to reduce refill frequency and fill-failure risk

Looking Ahead

The structural factors driving Citric Acid/Sodium Citrate availability challenges — limited manufacturers, liquid formulation complexity, and low relative demand — are unlikely to resolve in the near term. Providers should treat intermittent unavailability as an expected part of the prescribing landscape for this medication and plan accordingly.

The most effective mitigation strategy remains proactive communication: discuss potential supply issues with patients when initiating therapy, identify backup medications, and use availability tools like Medfinder to help patients find stock efficiently.

Final Thoughts

Citric Acid/Sodium Citrate remains a valuable urinary alkalinizer with a well-established safety and efficacy profile. While availability challenges can disrupt patient care, providers who plan proactively — by considering therapeutic alternatives, leveraging availability tools, and maintaining open communication with patients — can minimize the impact of supply disruptions.

For patient-facing resources on this topic, consider sharing these articles:
Citric Acid/Sodium Citrate Shortage Update for Patients
Alternatives to Citric Acid/Sodium Citrate
How to Find Citric Acid/Sodium Citrate in Stock